

NE
In table 1, page 38, line 11, after "CCG" please insert -(SEQ.I.D. NO. 13)-.

In table 1, page 38, line 12, after "R R" please insert -(SEQ.I.D. NO. 14)-.

In table 1, page 38, line 13, after "CCG" please insert -(SEQ.I.D. NO. 15)-.

NE
In table 1, page 38, line 14, after "R R" please insert -(SEQ.I.D. NO. 16)-.

Please incorporate the enclosed nine pages of Sequence Listing after page 40, and renumber pages 50 through 52 accordingly.

IN THE CLAIMS:

09/02/2009 01:24:00
Sub C1 1. (Amended) A peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1, said peptide comprising the sequence VLXDDLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

2. (Amended) An immunogenic polypeptide obtainable from the minor Histocompatibility antigen HA-1, said immunogenic polypeptide comprising the sequence VLXDDLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

3. (Amended) [A peptide or] The immunogenic polypeptide [according to] of claim 1 or 2, comprising the sequence VLHDDLLEA] 2, wherein X represents a histidine residue.

Sub 4.21
(Amended) [Vaccine] A vaccine comprising [an epitope or a] the immunogenic polypeptide [according to any one of claims 1-3] of claim 2.

5. (Amended) A pharmaceutical formulation comprising [an epitope or a] the immunogenic polypeptide [according to any one of claims 1-3] of claim 2.

Please cancel claim 6.

7. (Amended) [Use of a peptide or] A method of inducing tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease in a subject, said method comprising using, with said subject, the immunogenic polypeptide [according to claims 1-3 in the preparation of a medicament] of claim 2 for the induction of tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease.

8. (Amended) A method for the elimination of a group of (neoplastic) hematopoietic cells presenting a peptide or immunogenic polypeptide in the context of HLA class I [according to any of one of claims 1-3, whereby] of claim 2 wherein said elimination is induced directly [of] or indirectly by specific recognition of said [peptide] immunogenic polypeptide in said context.

9. (Amended) [Analog] An analog of [the peptide according to claim 1] a peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1, said peptide comprising the sequence VLXDPLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue, which analog is an antagonist for the activity of T cells recognizing said peptide.

10. (Amended) [Method] A process for [the generation of] producing antibodies, T cell receptors, anti-idiotypic B-cells or T-cells, said process comprising [the step of immunization of] immunizing a mammal with [a peptide or a] the immunogenic polypeptide [according to] of claim [1 or] 2, thus inducing production of said antibodies, T cell receptors, anti-idiotypic B-cells or T-cells in the mammal.

11. (Amended) Antibodies, T-cell receptors, B-cells or T-cells obtainable by the [method] process of claim 10.

12. (Amended) A [method] process for the [generation] production of a cytotoxic T-cell against a minor antigen, said process comprising:

contacting a hematopoietic cell[, preferably a dendritic cell with a peptide, preferably in the context of HLA class I, or a] with the immunogenic polypeptide [according to anyone]

of [claims 1-3]claim 2.

13. (Amended) [A method]The process according to claim 12, wherein said hematopoietic cell is ~~negative~~ for said minor antigen.

14. (Amended) [A method]The process according to claim 12 [or 13], wherein said minor antigen is HA-1.

15. (Amended) [A method]The process according to [any one of claims 12-14]claim 12 wherein said contacting of the hematopoietic cell with a peptide or an immunogenic polypeptide is carried out ex vivo.

16. (Amended) [A method]The process according to [any one of claims 12-15]claim 12, wherein said cytotoxic T-cell is provided with a suicide gene.

17. (Amended) [A method]The process according to [anyone of claims 12-16, whereby]claim 12 wherein said cytotoxic T-cell is immortalized.

18. (Amended) A cytotoxic T-cell or a derivative or an active fragment thereof, obtainable by [a method according to any one]the process of [claims 12-17]claim 12.

19. (Amended) [A]The cytotoxic T-cell [according to]of claim 18, which is capable of expansion.

Remarks

The application is to be amended as previously set forth. All amendments, including claim cancellations, are made without prejudice or disclaimer. The amendments are made to bring the application closer to United States practice, such as, by example, removing multiple claim dependencies. It is respectfully submitted that no new matter has been added by the amendment.